PDQ-39 measures Health-related Quality of Life in Mirapex Study
7th September 2022
New study data has shown that Mirapex significantly boosted Health-related Quality of Life (HRQoL) in patients with early Parkinson’s.
Mirapex (pramipexole) is a therapy produced by Boehringer Ingelheim to treat the motor symptoms of Parkinson’s disease. It is available as immediate release (IR) or extended release (ER) tablets.
The Parkinson’s disease questionnaire (PDQ-39) – ” the most widely used Parkinson’s-specific health-related QoL questionnaire” was used during the study to measure HRQoL.
“Of 80 eligible articles screened, six trials consisting of at least 2000 patients with early or advanced PD were included. From the synthesis of all six selected trials, a significant mean change from baseline in the PDQ-39 total score of –2.49 (95% CI, –3.43 to –1.54; p < 0.0001) was observed with pramipexole compared with placebo”
The PDQ-39 is a self completion PRO designed to address aspects of functioning and well-being for those affected by Parkinson’s disease.
The PDQ is the most comprehensive Parkinson’s disease assessment questionnaire because it is:
- simple to complete so benefits from an excellent response rate
- proven by validation and feasibility studies (reported in the manual) covering topics such as cross-cultural evaluation
- supported by a comprehensive 114 page user manual
- available in over 80 language versions
- available in the 39-item PDQ-39 or the short form PDQ-8 (8 items)
- can be supported by expert advice available from the developers for the use, delivery and data assessment of the PDQ
More information about the study can be found here.
Press release sign up
